Avantor, Inc. (NYSE:AVTR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Avantor, Inc. (NYSE:AVTR) have been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $27.57.

AVTR has been the subject of several recent research reports. Stifel Nicolaus increased their target price on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Wells Fargo & Company dropped their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Morgan Stanley upped their price objective on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. TD Cowen upped their price objective on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, July 29th. Finally, Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and cut their target price for the stock from $30.00 to $23.00 in a research note on Wednesday, July 10th.

Insider Activity

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its position in Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares during the last quarter. UMB Bank n.a. acquired a new position in shares of Avantor during the third quarter worth $49,000. Nisa Investment Advisors LLC lifted its stake in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after acquiring an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after acquiring an additional 1,285 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Trading Up 1.0 %

Shares of NYSE:AVTR opened at $22.78 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm has a market cap of $15.50 billion, a price-to-earnings ratio of 49.52, a PEG ratio of 2.70 and a beta of 1.35. Avantor has a 12 month low of $18.02 and a 12 month high of $28.00. The company’s fifty day simple moving average is $25.08 and its 200 day simple moving average is $24.15.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.